Abstract-mPGES-1 (microsomal prostaglandin E synthase-1), the downstream enzyme responsible for PGE 2 (prostaglandin E 2 ) synthesis in inflammatory conditions and oxidative stress are increased in vessels from hypertensive animals. We evaluated the role of mPGES-1-derived PGE 2 in the vascular dysfunction and remodeling in hypertension and the possible contribution of oxidative stress. We used human peripheral blood mononuclear cells from asymptomatic patients, arteries from untreated and Ang II (angiotensin II)-infused mPGES-1 −/− and mPGES-1 +/+ mice, and vascular smooth muscle cells exposed to PGE 2 . In human cells, we found a positive correlation between mPGES-1 mRNA and carotid intima-media thickness (r=0.637; P<0.001) and with NADPH oxidase-dependent superoxide production (r=0.417; P<0.001). In Ang IIinfused mice, mPGES-1 deletion prevented all of the following: (1) the augmented wall:lumen ratio, vascular stiffness, and altered elastin structure; (2) the increased gene expression of profibrotic and proinflammatory markers; (3) the increased vasoconstrictor responses and endothelial dysfunction; (4) the increased NADPH oxidase activity and the diminished mitochondrial membrane potential; and (5) the increased reactive oxygen species generation and reduced NO bioavailability. In vascular smooth muscle cells or aortic segments, PGE 2 increased NADPH oxidase expression and activity and reduced mitochondrial membrane potential, effects that were abolished by antagonists of the PGE 2 receptors (EP), EP1 and EP3, and by JNK (c-Jun N-terminal kinase) and ERK1/2 (extracellular-signal-regulated kinases 1/2) inhibition. Deletion of mPGES-1 augmented vascular production of PGI 2 suggesting rediversion of the accumulated PGH 2 substrate. In conclusion, mPGES-1-derived PGE 2 is involved in vascular remodeling, stiffness, and endothelial dysfunction in hypertension likely through an increase of oxidative stress produced by NADPH oxidase and mitochondria. (Hypertension. 2018;72:492-502.
H ypertension is characterized by vascular functional alterations such as increased vasoconstrictor responses and endothelial dysfunction. 1 In addition, increased wall:lumen ratio, changes in collagen and elastin, and increased vessel stiffness are additional hallmarks of hypertensive vascular disease and are largely dependent on the renin-angiotensin system. [1] [2] [3] Importantly, different evidence suggest a key role of chronic inflammation and vascular infiltration of immune inflammatory cells as underlying mechanisms responsible for these vascular alterations. 4, 5 In physiological conditions, prostanoids such as PG (prostaglandins) E 2 , PGI 2 , PGD 2 , or PGF 2α , and thromboxane A 2 are synthesized by the constitutive COX (cyclooxygenase)-1 enzyme. In inflammatory conditions, the production of these mediators, particularly PGE 2 , is greatly enhanced by the action of the inducible COX-2. 6 Moreover, the mPGES-1 (microsomal prostaglandin E synthase-1), a COX-2 downstream enzyme, controls both baseline and inducible PGE 2 production and participates in various physiological and pathological processes, including inflammation, pain, fever, blood pressure regulation, atherogenesis, and cancer. 6 As a membrane protein, mPGES-1 is found in the microsomal fraction. 6 The enzyme displays perinuclear and endoplasmic reticulum staining, 6 and localization of mPGES-1 within the Golgi apparatus has been recently described. 7 Interestingly, mPGES-1 is in closed proximity with COX-2 6, 7 and efforts are being made to confirm whether this physical proximity might be the basis for an efficient biosynthetic interaction between both enzymes for the synthesis of PGE 2 . 6, 7 Proinflammatory stimuli that induce COX-2 are also able to induce mPGES-1. 6 In fact, besides COX-2, Ang II (angiotensin II) upregulates mPGES-1 in vascular cells 8, 9 and increased PGE 2 production and mPGES-1 expression are observed in vessels from several models of hypertension or in peripheral blood mononuclear cells (PBMCs) from hypertensive patients. 8, 10, 11 PGE 2 modulates vascular tone through 4 PGE 2 receptor (EP) subtypes (EP 1-4 ). As a broad generalization, EP 1 and EP 3 receptors mediate excitatory and contractile effects, whereas EP 2 and EP 4 receptors mediate inhibitory and vasodilator effects. 12 The COX-2/mPGES-1/EP pathway is a key mediator of vascular remodeling in atherosclerosis, aneurysms, and restenosis. 9, [13] [14] [15] [16] [17] [18] About vascular function, it has been demonstrated that prostanoids are involved in the hypercontractility and endothelial dysfunction observed in hypertension 8, 19, 20 and that mPGES-1 modulates vascular tone in human arteries. 21 In this sense, we have recently reported that EP 1 receptors blockade prevents the vascular stiffness and endothelial dysfunction in the setting of Ang II-induced hypertension. 8, 22 However, the role of mPGES-1 in these alterations and the intracellular mechanisms responsible are largely unknown and to our knowledge, only our previous study reported a beneficial effect of mPGES-1 deletion in Ang II-induced aortic hypertrophy. 10 It is accepted that reactive oxygen species (ROS) generation has a key role in vascular alterations in hypertension. 23 Previous evidence in hepatic cells 24 or in vessels from animal models of hypertension and hypertensive patients 20, 22 suggested that COX-2-derived prostanoids such as PGE 2 might activate ROS formation from NADPH oxidase and mitochondria, the 2 major sources of ROS at vascular level. Moreover, PGE 2 acting on EP 1 25 or EP 3 26 receptors facilitates oxidative stress generation in inflammatory conditions in different cell types. Global 9 or myeloid cells specific 27 deletion of mPGES-1 were concomitant with vascular oxidative stress reduction in a model of Ang II-induced aneurysms and in atherosclerosis, respectively. However, using a low dose of Ang II Jia et al 11 found augmented oxidative stress in mPGES-1 −/− mice compared with their counterpart wild-type. Whether this is also observed in a model of Ang II-induced hypertension and whether this has a role in the Ang II-associated vascular damage is unknown.
We hypothesized that an increased expression and activity of mPGES-1 would participate in the vascular remodeling, stiffening, and endothelial dysfunction found in hypertension through increased ROS generation. We used PBMCs from asymptomatic subjects, arteries from a model of Ang II-induced hypertension in wild-type and mPGES-1 knockout mice and cultured vascular cells. We evaluated vascular function, remodeling, stiffness, ROS generation from NADPH oxidase, and mitochondria and intracellular signaling pathways.
Material and Methods
An expanded Materials and Methods is available in the online-only Data Supplement. The authors declare that all supporting data are available within the article (and its online-only Data Supplement).
Patients and Animal Models
Studies in patients were performed in accordance with the Declaration of Helsinki. The animals were handled according to animal welfare regulations and protocols approved by the authors' Institutional Review Boards.
Statistical Analysis
All data are expressed as mean values±SEM, and n represents the number of animals, different cultures, or patients studied. Results were analyzed by the Mann-Whitney nonparametric or Student t tests when appropriate (2-tailed) or 1-way or 2-way ANOVA followed by Bonferroni post hoc test by using GraphPad Prism Software. Univariate association was performed by Pearson correlation test. Multivariate linear regression analysis was conducted with carotidintima media thickness (IMT) as dependent variable, including in the model the traditional risk factors and those variables that were significant in the univariate analysis. A P<0.05 was considered significant.
Results

mPGES-1 Expression in PBMCs of Patients
mPGES-1 mRNA levels are increased in PBMCs from a small group of naive hypertensive patients, 8 and PBMCs superoxide generation correlates with vascular remodeling. 28 We evaluated mPGES-1 mRNA levels in PBMCs in a population of 156 asymptomatic subjects in which left carotid IMT, a marker of vascular remodeling, and phagocytic superoxide production were also measured.
A univariate analysis showed a positive correlation between mPGES-1 mRNA and carotid IMT ( Figure 1A ; Table S2 in the online-only Data Supplement) and between mPGES-1 and superoxide production ( Figure 1B ; Table  S2 ). Interestingly, mPGES-1 mRNA also positively correlated with systolic and diastolic blood pressure (Table S2) . Notably, the association between mPGES-1 and carotid IMT remained significant after adjusting for traditional risk factors (Table S3) .
Role of mPGES-1 in Vascular Remodeling, Stiffness, and Inflammation in Hypertension
We have described that Ang II infusion increased mPGES-1 expression and PGE 2 production.
8 mPGES-1 deletion prevented the increase in PGE 2 production induced by Ang II infusion in mesenteric resistance arteries ( Figure S1A ). Systolic blood pressure was similar in untreated mPGES-1 +/+ and mPGES-1 −/− mice ( Figure S1B ). Ang II increased systolic blood pressure slightly slower in mPGES-1 −/− than in mPGES-1 +/+ mice, reaching similar levels at the end of the treatment ( Figure S1B ).
Mesenteric resistance arteries from untreated mPGES-1 +/+ and mPGES-1 −/− mice showed similar vascular structure, mechanical properties, elastin structure, and gene expression of profibrotic and proinflammatory markers (Figure 2 ). In mPGES-1 +/+ mice, Ang II infusion augmented wall:lumen ratio and vascular stiffness (shown by decreased incremental distensibility, leftward shift of the stress-strain relationship, and increased β value) and altered elastin structure (shown by decreased fenestrae area and number) (Figure 2A through 2D). Ang II also increased wall:lumen ratio and vascular stiffness in mPGES-1 −/− mice but this effect was smaller than in mPGES-1 +/+ mice; moreover, in mPGES-1 −/− mice Ang II did not modify elastin structure (Figure 2A through 2D) .
Increased mRNA levels of CTGF (connective tissue growth factor), PAI-1 (plasminogen activator inhibitor-1), monocyte CCL2 (chemoattractant protein chemokine [C-C motif] ligand 2 ), macrophage infiltration marker Mac-3 (lysosomal-associated membrane protein 2), TNF (tumor necrosis factor)-α, and IFN (interferon)-γ were observed in aorta from Ang II-infused mPGES-1 +/+ mice. mPGES-1 deletion normalized CTGF, PAI-1, Mac-3, TNF-α, and IFN-γ mRNA levels, but it did not modify Ang II-induced CCL2 levels ( Figure 2E ).
Role of mPGES-1 in Vascular Dysfunction and NO Bioavailability in Hypertension
Aorta from mPGES-1 +/+ and mPGES-1 −/− mice showed similar vasoconstrictor and endothelium-dependent vasodilator responses ( Figure 3A and 3B). Ang II infusion increased phenylephrine-induced vasoconstrictor responses and diminished vasodilator responses to acetylcholine in both genotypes; however, these effects were smaller in mPGES-1 −/− than mPGES-1 +/+ mice ( Figures 3A and B) . No differences in vasodilator responses to diethylamine NONOate were observed between the 4 groups of mice ( Figure 3C ).
We then evaluated the role of mPGES-1 on vascular NO bioavailability and its contribution to vasoconstrictor responses. The NOS inhibitor N-nitro-l-arginine methyl ester (L-NAME) similarly leftward-shifted the phenylephrine-induced contraction in aorta from both untreated mPGES-1 +/+ and mPGES-1 −/− mice ( Figure 3D ). Notably, after Ang II infusion, L-NAME leftward shift phenylephrine responses in mPGES-1 −/− but not in mPGES-1 +/+ mice ( Figure 3D ). Accordingly, NO release was significantly reduced only in aorta from Ang II-infused mPGES-1 +/+ mice ( Figure 3E ). Together these results suggest that mPGES-1 deletion increases NO bioavailability, which improves the Ang II-induced vascular dysfunction. −/− mice Ang II failed to increase all parameters of vascular oxidative stress with the exception of NOX-1 mRNA, which was still increased by Ang II, although to a lesser extent than in mPGES-1 +/+ mice ( Figure 4A through 4E). Mitochondrial ROS are also important for hypertension-associated vascular damage. 29 Mitochondrial membrane potential was similar in arteries from both genotypes ( Figure 4F ). Ang II infusion reduced this parameter only in mPGES-1 +/+ mice ( Figure 4F ). Next, we analyzed the role of ROS from NADPH oxidase and mitochondria in vascular responses. The nonselective NADPH oxidase inhibitor ML171 or the mitochondria-targeted superoxide dismutase mimetic mito-TEMPO did not affect vasodilator responses in untreated mPGES-1 +/+ and mPGES-1 −/− mice; however, after Ang II infusion, both drugs improved endothelial function in segments from mPGES-1 +/+ mice ( Figure 5) . Notably, no effect of ML171 or mito-TEMPO was observed in arteries from Ang II-infused mPGES-1 −/− mice ( Figure 5 ). Furthermore, neither ML171 nor mito-TEMPO modified phenylephrine responses in untreated mPGES-1 +/+ or mPGES-1 −/− mice ( Figure S2 ), but they reduced the responses to phenylephrine only in aorta from mPGES-1 +/+ Ang II-infused mice ( Figure S2 ). Altogether, these results suggest the involvement of mPGES-1 in the activation of NADPH oxidase and mitochondrial ROS production and its contribution to the impairment of vascular responses in Ang II-induced hypertension.
Role of mPGES-1 in Oxidative Stress in
Alterations in antioxidant defense systems can also underlie the increased oxidative stress. Superoxide dismutase, catalase, and GPx (glutathione peroxidase) activities were greater in plasma from untreated mPGES-1 −/− than in mPGES-1 +/+ mice ( Figure S3 ), suggesting increased antioxidant protection after mPGES-1 deletion. Ang II infusion differently affected antioxidant activities in both groups of mice. Thus, Ang II increased and decreased GPx activity. However, in mPGES-1 −/− mice, Ang II did not affect superoxide dismutase activity, increased catalase activity, and slightly decreased GPx activity; in these conditions, both catalase and GPx activities were greater in mPGES-1 −/− than in mPGES-1 +/+ mice ( Figure S3 ). 
Role of EP 1 and EP 3 Receptors in Oxidative Stress
PGE 2 /EP 1 pathway facilitates the NADPH oxidase activation induced by Ang II in the cerebral vasculature 25 and other evidence suggest a role of EP 3 receptors in oxidative stress generation in different cell types. 26 We then evaluated the role of EP 1 and EP 3 receptors in the increased oxidative stress induced by Ang II. Mouse aortic segments incubated ex vivo with Ang II (1 μmol/L, 4 hours) showed increased NADPH oxidase activity and decreased mitochondrial membrane potential, effects that were abolished by the EP 1 antagonist SC51322 ( Figure S4A and S4B). The EP 3 antagonist L798106 also restored NADPH oxidase activity but not mitochondrial membrane potential ( Figure S4A and S4B) . These results suggest that PGE 2 contributes to the Ang II-induced ROS production. Accordingly, in aortic segments from control mice the cell-permeable available synthetic PGE 2 16,16-dimethyl PGE 2 (DPGE 2 , 5 μmol/L, 4 hours), increased NADPH oxidase activity and reduced mitochondria membrane potential, effects that were restored by SC51322 and L798106 ( Figure S4C and S4D ). This had a functional consequence because the contractile responses induced by DPGE 2 (3 μmol/L) were reduced by ML171, mito-TEMPO, catalase, and apocynin ( Figure S4E ). In cultured vascular smooth muscle cells (VSMC), DPGE 2 (5 μmol/L) time-dependently increased NADPH oxidase activity and NOX-1 mRNA levels ( Figure S5A and S5B). DPGE 2 (1 nmol/L) also increased NADPH oxidase activity and NOX-1 mRNA levels in mouse aortic VSMC (data not shown). Moreover, the DPGE 2 -induced NADPH oxidase activation, NOX-1 mRNA, and O 2 −. production were prevented by SC51322 and L798106 ( Figure S5C through  S5E) . Notably, DPGE 2 also increased NADPH oxidase activity and NOX-1 mRNA levels in cultured human endothelial cells ( Figure S5F through S5H) .
Role of JNK and ERK1/2 in PGE 2 -Induced Oxidative Stress
We then studied in VSMC, the intracellular mechanisms involved in the increased oxidative stress induced by PGE 2 . The p38 MAPK (mitogen-activated protein kinase) inhibitor SB203580, the PI3K inhibitor LY294002, and the PKC inhibitor staurosporine did not affect the DPGE 2 -induced NADPH oxidase activity ( Figure 6A) ; however, U0126 and SP600125, respective MEK (MAPK kinase, ERK1/2 [extracellular-signal-regulated kinases 1/2]) and JNK (c-Jun N-terminal kinase) inhibitors, abolished the DPGE 2 -induced NADPH oxidase activity, NOX-1 mRNA levels, and O 2 −. production ( Figure 6A through 6C) . Accordingly, DPGE 2 time-dependently increased p-JNK and p-ERK expression, which were significant at 10 minutes ( Figure 6D and 6E) . These data indicate that PGE 2 activates JNK and ERK1/2 that increase oxidative stress.
Role of PGI 2 in Vascular Function
The rediversion of the mPGES-1 substrate PGH 2 toward PGI 2 synthase thereby enhancing vasoprotective PGI 2 biosynthesis has been observed in mPGES-1 knockout mice. 30 As shown in Figure S6A , PGI 2 production was greater in aorta from untreated mPGES-1 −/− than mPGES-1 +/+ mice. We then tested the effect of PGI 2 on the vascular alterations induced by Ang II. PGI 2 did not affect phenylephrine responses in control arteries; however, PGI 2 incubation clearly prevented the enhancement in contractile responses induced by Ang II (1 μmol/L, 4 hours; Figure S6B ).
Discussion
Nonsteroidal anti-inflammatory drugs (NSAIDs) increase cardiovascular risk, thereby augmenting the risk of stroke and myocardial infarction, which seems to be attributable to suppression of COX-2-derived cardioprotective PGI 2 , among other potential factors. 31 This concern about the cardiovascular safety of NSAIDs has prompted interest in alternative targets, such as mPGES-1. In fact, several studies have evaluated the cardiovascular effects of blockade of this enzyme with limited information of its consequence in hypertension-associated vascular damage. This enzyme seems to be the dominant source of excessive PGE 2 in hypertension, as reflected by marked suppression of PGE 2 in arteries from mPGES-1 −/− Ang II-infused mice. More importantly, we demonstrate that mPGES-1 is a key enzyme involved in the vascular alterations observed in hypertension. Thus, the harmful effects of Ang II on vascular function, wall:lumen ratio, vessel stiffness, extracellular matrix proteins, and profibrotic and proinflammatory factors were smaller in vessels from mPGES-1 −/− than in wild-type mice. Of note, untreated mPGES-1 −/− mice have normal vascular structure and function, whereas arteries from COX-2 −/− mice showed increased wall:lumen ratio, vascular stiffness and some degree of endothelial dysfunction when compared with wild-type mice, 8 suggesting that mPGES-1 inhibitors might be less prone to vascular complications than NSAIDs.
Different studies have identified the contribution of mPGES-1 located in specific cell compartments to vascular damage. Thus, mPGES-1 depletion in myeloid cells restrains the initiation and early development of atherosclerosis with few effects observed after mPGES-1 deletion in VSMC or endothelial cells. 27 In the wire-induced vascular injury model, global 16 and myeloid cell-specific 32 mPGES-1 deletion attenuated the proliferative response to vascular injury; however, this response was increased when mPGES-1 was deleted from endothelial cells and SMC. 32 Our data on global knockout mice do not allow to clearly define which cell type is responsible for the mPGES-1-derived vascular damage in hypertension. However, given the contractile and prooxidant effects of PGE 2 observed in VSMC in the present study and the robust expression of mPGES-1 in the media layer of Ang II-infused mice observed in our previous study, 8 we propose VSMC as key location of mPGES-1 to originate vascular damage. Moreover, because of the influence of inflammatory cells in hypertension-associated vascular damage, we cannot discard a contribution of mPGES-1 from myeloid cells. In fact, we recently observed increased mPGES-1 expression in circulating mononuclear cells from untreated hypertensive patients compared with normotensive individuals. 8 More importantly, a positive correlation between PBMCs mPGES-1 mRNA levels, blood pressure, and IMT was observed in asymptomatic patients, and this correlation remained significant after adjustment for traditional risk factors. Interestingly, mPGES-1 deletion clearly prevented Ang II-induced macrophage infiltration and TNF-α and IFN-γ expression, suggesting that mPGES-1 also modulates vascular inflammation in the setting of hypertension as described in atherosclerosis. 27 Our previous findings suggest a contribution of EP 1 receptors in the vascular alterations associated with Ang II-dependent hypertension. 8, 22 Interestingly, a role for EP 3 receptors in the neointima hyperplasia formation 17 and in the acute vasoconstrictor responses induced by Ang II 33 has also been described. EP 1/3 receptors contribute to oxidative stress generation in different experimental conditions. 25 , 26 We herein demonstrate that mPGES-1 might be a novel contributor to the enhanced oxidative stress found in hypertension, because mPGES-1 deficient mice are protected against the increased NADPH oxidase activity and expression, the altered mitochondrial membrane potential and the increased vascular H 2 O 2 and O 2 −. production induced by Ang II. Moreover, a positive correlation was found between mPGES-1 and O 2 −. production in PBMCs from patients. This increased ROS production derived from the mPGES-1 pathway likely decreases NO availability and explains, at least in part, the increased vasoconstrictor responses and the endothelial dysfunction observed after Ang II treatment. Accordingly, the NADPH oxidase activity and the diminished mitochondrial membrane potential induced by Ang II were prevented ex vivo by EP 1 and EP 3 blockade. Moreover, a PGE 2 analog induced NADPH oxidase activation and upregulation, O 2 −. production and mitochondrial alterations, effects that were blocked by EP 1 and EP 3 antagonism. Finally, the DPGE 2 -induced contractile responses were inhibited by several antioxidants. Again, although our data strongly support the key role of VSMC as the potential source of ROS in response to PGE 2 , we cannot discard the contribution of other cell types in the in vivo model. Thus, as discussed earlier, mPGES-1 deletion also decreased infiltration of macrophages, which are known sources of oxidative stress. Notably, PGE 2 also induced oxidative stress in endothelial cells. PGE 2 binds to EP 1 and EP 3 receptors and activates several intracellular signaling pathways. 34 In VSMC, JNK, and MEK/ERK1/2 inhibitors abolished the PGE 2 -induced NADPH oxidase activity and NOX-1 mRNA levels, whereas inhibition of p38MAPK, PI3 kinase, and PKC did not. Accordingly, PGE 2 activated both JNK and ERK1/2, which are activators of NOX-1 expression and activity in response to several stimuli. 35 Importantly, plasma catalase and GPx activities were augmented in mPGES-1 deficient mice irrespective of the presence of Ang II, findings that together with the lower expression of NOX-4, a known source of H 2 O 2 , suggest high capacity of mPGES-1 deletion to decrease H 2 O 2 levels.
Few reports have to date analyzed the role of mPGES-1 in vascular oxidative stress and with contradictory results. Thus, in agreement with our findings, Wang et al 9 demonstrated that mPGES-1 deletion decreased systemic and aortic markers of oxidative stress in a model of Ang II-dependent aneurysms. In addition, specific deletion of mPGES-1 in myeloid cells also decreased oxidative stress in a model of atherosclerosis. 27 However, Jia et al 11 showed increased activity and expression of NADPH oxidase in mPGES-1 knockout mice when compared with wild-type, in response to a much lower dose of Ang II during shorter times. In fact, in this study, Ang II did not increase blood pressure in wild-type mice, although an increase in blood pressure was observed after mPGES-1 deletion. 11, 36 Our results on tail-cuff blood pressure measurements agree with previous studies, demonstrating similar hypertensive effects of Ang II in mPGES-1 +/+ and mPGES-1 −/− in hyperlipidemic 9 or normal mice 37, 38 at the dose of Ang II used in the present study, although a slightly slower Ang II effect was observed at earlier time points, that might have eventually contributed to improve vascular responses. Additional explanations for these divergent results likely include differences in the background of the animals, as previously suggested. 38 Clinical studies will need to be designed to ascertain whether mPGES-1 inhibitors have a safer blood pressure profile compared with COX-2 selective NSAIDs.
Enhanced PGI 2 biosynthesis as a consequence of rediversion of the mPGES-1 substrate has been observed in mPGES-1 −/− mice 30 and in patients treated with mPGES-1 inhibitors. 39 Accordingly, we observed augmented local generation of PGI 2 in arteries from mPGES-1 −/− mice. Although we did not measure PGI 2 production after Ang II infusion, Wang et al 9 reported that in hyperlipidemic mice mPGES-1 deletion further augmented the production of PGI 2 after Ang II. The enhanced PGI 2 biosynthesis might provide therapeutic potential in mPGES-1 knockout mice in atherogenesis, 18 abdominal aortic aneurysm 9 and in vascular proliferation after injury, 16 and we cannot affirm that the protective effect of mPGES-1 deletion in our experimental paradigm derives only from suppression of PGE 2 without a contribution of other COX products such as PGI 2 . In fact, mPGES-1 inhibitors reduce human vascular tone by increasing PGI 2 , 21 and we observed that ex vivo PGI 2 decreases the Ang II-induced hypercontractility. Notably, PGI 2 seems to have antioxidant properties at vascular level, 40, 41 which might eventually contribute to the lower oxidative stress observed in mPGES-1 −/− mice. Only a more comprehensive study using double knockout mice on mPGES-1 and prostaglandin I 2 receptors, as used in atherosclerosis, thrombosis, or neointima formation, 42, 43 would provide the definitive experimental proof of the role of PGI 2 in the beneficial vascular effects of mPGES-1 deletion in Ang II-dependent hypertension.
In conclusion, our results suggest that mPGES-1-derived PGE 2 acting on EP 1 /EP 3 receptors and activating JNK/ERK1/2 pathways contributes to the excessive ROS levels derived from NADPH oxidase and mitochondria in response to Ang II. In turn, this pathway would contribute to vascular dysfunction, remodeling, increased stiffness, and inflammation observed in hypertension. Many experimental evidence support a relationship between oxidative stress and vascular damage in hypertension. 23, 29 We propose that targeting mPGES-1/ ROS pathway might be a promising option for treatment of hypertension-associated vascular dysfunction.
Perspectives
It is well accepted that NSAIDs confer a cardiovascular hazard, which has prompted interest in mPGES-1 as a novel target to decrease inflammation with a safer cardiovascular profile. We demonstrate, for the first time, that mPGES-1-derived PGE 2 is involved in the development of vascular damage in hypertension by increasing oxidative stress from NADPH oxidase and mitochondria and by decreasing antioxidant defenses, effects that likely reduce NO bioavailability. Therefore, limiting this pathway seems to provide vascular safety and might provide potential utility as therapeutic target in vascular dysfunction in hypertension.
